logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Dollar Bond Movement | Prolos GLPSP 4.5 PERP price fell by 1.509% to 44.456.

date
19/03/2026
GLPSP 4.5 PERP, issued by Prose on March 19th, is currently priced at 44.456, a decrease of -1.509%, with a yield of 2682.331%.
Latest
4 m ago
Institution: Singapore's yuan rose slightly due to low inflation risks.
5 m ago
Institution: Palm oil prices may remain above 4,450 ringgit per ton.
5 m ago
Olivier Darcy, Chief Investment Decision Researcher for SimCorp Asia-Pacific, stated that central banks do not take any risks in their actions. Therefore, when faced with external shocks such as Liberation Day tariffs, the COVID-19 pandemic, or similar events, they tend to temporarily step back and pause their actions, saying "we need data." We saw the Fed take this hedge measure last night, and it appears that the Bank of Japan is also taking a similar approach. After the situation calms down this year, the Bank of Japan may continue to raise interest rates. However, the market does not agree with the Bank of Japan's policy of limiting long-term bond yields through bond purchases. The yen has been punished due to the Bank of Japan's restriction on long-term bond yields. Whether it is the Fed meeting, Bank of Japan meeting, or European Central Bank meeting, there is much greater disagreement than before. This precisely reflects the lack of confidence in the data.
6 m ago
On March 19, AstraZeneca announced plans to establish a commercial production and innovation center for cell therapy in Shanghai. On the same day, the company signed a memorandum of understanding for multi-party cooperation with the Shanghai Science and Technology Committee and leading research and financial institutions in the UK. AstraZeneca will build a dedicated commercial production and supply base for cell therapy in the Lingang New Area of the Shanghai Free Trade Zone for the commercial production and supply of autologous CAR-T cell therapy in China and other Asian markets. This includes AZD0120, a BCMA/CD19 dual-target CAR-T cell therapy developed based on the FasTCAR rapid production platform from Genwell Bio. (Jiemian)
6 m ago
Accumulated freight volume exceeds 500 million tons, highlighting the role of the Haoji Railway's "North Coal South Transport" major transportation corridor.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.